NASDAQ:IMRX | Free Cash Flow | Immuneering Corp

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$18.43M$79,930.00-$18.51M
2025-12-31-$9.84M$123,910.00-$9.96M
2025-03-31-$14.08M$8,945.00-$14.09M
2024-12-31-$14.51M$9,356.00-$14.52M
2024-03-31-$15.49M$37,478.00-$15.53M
2023-12-31-$11.78M$170,918.00-$11.95M
2023-03-31-$14.42M$27,993.00-$14.45M
2022-12-31-$11.75M$69,302.00-$11.82M
2022-03-31-$12.28M$115,050.00-$12.4M
2021-12-31-$9.24M$13,052.00-$9.25M
2021-03-31-$6.14M$16,564.00-$6.16M
2020-12-31-$5.45M$38,058.00-$5.49M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$45.34M$142,226.00-$45.49M
2024-12-31-$55M$84,875.00-$55.08M
2023-12-31-$48.97M$342,746.00-$49.31M
2022-12-31-$44.1M$742,483.00-$44.84M
2021-12-31-$30.85M$60,786.00-$30.91M
2020-12-31-$14.62M$53,415.00-$14.67M